pulmonary fibrosis
Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting amphiregulin and connective tissue growth factor in bleomycin or TGF-? transgenic animal models of pulmonary fibrosis.
Last, the in vivo silencing efficacy of SAMiRNAs was evaluated by targeting amphiregulin and <span class="gene" id="26817844-6-93-124">connective tissue growth factor</span> in bleomycin or TGF-&beta; transgenic animal models of <span class="disease" id="26817844-6-175-193">pulmonary fibrosis</span>.